Banco Santander’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $53.7M | Buy |
108,075
+8,687
| +9% | +$3.85M | 0.33% | 48 |
|
|
2026
Q1 | $44.4M | Buy |
99,388
+1,361
| +1% | +$635K | 0.36% | 42 |
|
|
2025
Q4 | $44.4M | Buy |
98,027
+18,621
| +23% | +$8.03M | 0.33% | 48 |
|
|
2025
Q3 | $31.1M | Buy |
79,406
+9,218
| +13% | +$3.85M | 0.28% | 63 |
|
|
2025
Q2 | $31.2M | Buy |
70,188
+6,160
| +10% | +$2.84M | 0.3% | 55 |
|
|
2025
Q1 | $31M | Buy |
64,028
+15,844
| +33% | +$7.38M | 0.34% | 46 |
|
|
2024
Q4 | $19.4M | Buy |
48,184
+32,316
| +204% | +$15M | 0.23% | 72 |
|
|
2024
Q3 | $7.38M | Sell |
15,868
-560
| -3% | -$269K | 0.09% | 152 |
|
|
2024
Q2 | $7.7M | Sell |
16,428
-525
| -3% | -$228K | 0.1% | 146 |
|
|
2024
Q1 | $7.09M | Sell |
16,953
-3,442
| -17% | -$1.46M | 0.09% | 148 |
|
|
2023
Q4 | $8.3M | Sell |
20,395
-2,160
| -10% | -$798K | 0.1% | 132 |
|
|
2023
Q3 | $7.84M | Sell |
22,555
-1,370
| -6% | -$479K | 0.11% | 123 |
|
|
2023
Q2 | $8.42M | Sell |
23,925
-5,530
| -19% | -$1.86M | 0.11% | 116 |
|
|
2023
Q1 | $9.28M | Sell |
29,455
-7,880
| -21% | -$2.36M | 0.14% | 85 |
|
|
2022
Q4 | $10.8M | Sell |
37,335
-4,135
| -10% | -$1.26M | 0.16% | 76 |
|
|
2022
Q3 | $12M | Sell |
41,470
-1,150
| -3% | -$331K | 0.16% | 71 |
|
|
2022
Q2 | $12M | Sell |
42,620
-12,572
| -23% | -$3.36M | 0.16% | 76 |
|
|
2022
Q1 | $14.4M | Buy |
55,192
+7,930
| +17% | +$1.88M | 0.15% | 87 |
|
|
2021
Q4 | $10.4M | Buy |
47,262
+1,300
| +3% | +$253K | 0.06% | 106 |
|
|
2021
Q3 | $8.34M | Buy |
45,962
+43,030
| +1,468% | +$8.4M | 0.04% | 126 |
|
|
2021
Q2 | $591K | Sell |
2,932
-1,324
| -31% | -$277K | ﹤0.01% | 314 |
|
|
2021
Q1 | $914K | Buy |
4,256
+357
| +9% | +$78.4K | 0.01% | 269 |
|
|
2020
Q4 | $921K | Sell |
3,899
-14,622
| -79% | -$3.35M | 0.01% | 259 |
|
|
2020
Q3 | $5.04M | Sell |
18,521
-107,431
| -85% | -$29.6M | 0.07% | 112 |
|
|
2020
Q2 | $36.6M | Sell |
125,952
-48,443
| -28% | -$13.1M | 0.47% | 15 |
|
|
2020
Q1 | $41.5M | Buy |
174,395
+74,906
| +75% | +$17.2M | 0.48% | 30 |
|
|
2019
Q4 | $21.8M | Buy |
99,489
+75,993
| +323% | +$15.4M | 0.2% | 54 |
|
|
2019
Q3 | $3.98M | Sell |
23,496
-95,083
| -80% | -$16.8M | 0.04% | 147 |
|
|
2019
Q2 | $21.7M | Sell |
118,579
-235,594
| -67% | -$41.2M | 0.22% | 42 |
|
|
2019
Q1 | $65.2M | Sell |
354,173
-898
| -0.3% | -$166K | 0.74% | 12 |
|
|
2018
Q4 | $58.8M | Sell |
355,071
-107
| -0% | -$18.5K | 0.74% | 13 |
|
|
2018
Q3 | $68.5M | Buy |
355,178
+1,924
| +0.5% | +$343K | 0.78% | 10 |
|
|
2018
Q2 | $60M | Buy |
353,254
+13,799
| +4% | +$2.14M | 0.7% | 14 |
|
|
2018
Q1 | $55.3M | Buy |
339,455
+2,655
| +0.8% | +$434K | 0.65% | 24 |
|
|
2017
Q4 | $50.5M | Buy |
336,800
+9,800
| +3% | +$1.45M | 0.72% | 15 |
|
|
2017
Q3 | $49.7M | Buy |
+327,000
| New | +$49.2M | 0.82% | 18 |
|
Other funds holding VRTX
DC
FAF
Banco Santander's VRTX Position: Q2 2026 in Review
Banco Santander increased its Vertex Pharmaceuticals (VRTX) stake by 8.7% in Q2 2026, buying an estimated $3.85M and bringing the position to 108,075 shares worth $53.7M. The position accounts for 0.33% of the portfolio, ranked #48.
Banco Santander first reported a position in VRTX in Q3 2017 and has held it in 36 quarters since. The position peaked at $68.5M in Q3 2018. 657 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Banco Santander held 108,075 shares of Vertex Pharmaceuticals worth $53.7M as of Q2 2026.
- Banco Santander bought 8,687 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.85M.
- Vertex Pharmaceuticals made up 0.33% of Banco Santander's portfolio in Q2 2026, its #48 holding.
- Banco Santander first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 36 quarters since.
- Banco Santander's Vertex Pharmaceuticals position peaked at $68.5M in Q3 2018.
- 657 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Banco Santander's 13F filing for Q2 2026, filed 29 Jul 2026.